You just read:

Elios Therapeutics Announces Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

Elios Therapeutics, LLC

Jun 01, 2018, 07:15 ET